



**THE FOUNDATION
FOR SECURE
MARKETS®**

#54648

Date: May 29, 2024
Subject: Inhibrx, Inc. - Distribution
Option Symbol: INBX
New Symbol: INBX1
Date: 05/30/2024

Contract Adjustment

Effective Date: May 30, 2024
Option Symbol: INBX changes to INBX1
Strike Prices: No Change
Number of Contracts: No Change
Multiplier: 100 (e.g., a premium of 1.50 yields \$150; a strike of 35 yields \$3,500.00)
New Deliverable Per Contract:
1) 100 Inhibrx, Inc. (INBX) Common Shares
2) 25 (New) Inhibrx Biosciences, Inc. (INXB) Common Shares
Settlement Allocation:
INBX: 90%
INXB: 10%
CUSIPs:
INBX: 45720L107
INXB: 45720N103

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

Pricing

The underlying price for INBX1 will be determined as follows:

$$\text{INBX1} = \text{INBX} + 0.25 (\text{INXB})$$

Background

Inhibrx, Inc. (INBX) has announced a distribution of (New) Inhibrx Biosciences, Inc. (INXB) Common Shares. The distribution ratio is 0.25 of an INXB share for each INBX share held. The record date is May 17, 2024; the payable date is May 29, 2024. The NASDAQ has set May 30, 2024, as the ex-distribution date for this distribution.

Inhibrx Biosciences, Inc. Common Shares began trading on a when issued basis on May 28, 2024 on the NASDAQ under the trading symbol "INXBV" and will start trading regular way on May 30, 2024 under the trading symbol "INXB". Following the completion of the merger of Inhibrx, Inc. (INBX) with Sanofi (SNY), INXB will change its symbol to INBX, which is expected to occur on or about May 31, 2024.

OCC is still awaiting notice of the effectiveness of the INBX merger with Sanofi (See OCC Information Memo #54605).

Disclaimer

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at options@theocc.com. Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.